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Introduction {#sec001}
============

Acute tonsillitis (AT) is a highly prevalent infection that is responsible for a large number of consultations. Peritonsillar abscess (PTA) is the most common deep head and neck infection, with an incidence of 10--41/100,000 \[[@pone.0228122.ref001]--[@pone.0228122.ref005]\], and traditionally regarded as a purulent complication of AT, but the evidence for an association between the two is uncertain. PTA may appear after tonsillectomy (TE) without tonsillar remnants, as Windfuhr et al. demonstrated, and the seasonal incidence of the two entities does not follow a symmetrical pattern \[[@pone.0228122.ref001], [@pone.0228122.ref006]--[@pone.0228122.ref008]\]. Over the last three decades, PTA has been speculated to not necessarily arise from AT, but as a consequence of poor dental health, smoking, and salivary dysfunction. Minor salivary glands have been suggested to play a significant role in PTA \[[@pone.0228122.ref003], [@pone.0228122.ref008], [@pone.0228122.ref009]\].

Shared symptoms of AT and PTA are sore throat and fever. PTA patients also suffer from trismus, and the pain is typically asymmetrical \[[@pone.0228122.ref010], [@pone.0228122.ref011]\]. In both AT and PTA, common clinical findings include tonsillar exudate and enlarged cervical lymph nodes. PTA patients also often have asymmetric peritonsillar swelling \[[@pone.0228122.ref011], [@pone.0228122.ref012]\]. The diagnosis of AT and PTA is clinical, but a recent review recommended measuring C-reactive protein (CRP) and performing a full blood count in all PTA patients, though the benefits of laboratory tests in the diagnosis or treatment of PTA are unclear. As dehydration is a common symptom of PTA, electrolytes should also be analyzed \[[@pone.0228122.ref002]\]. Tachibana et al. reported higher serum leukocyte levels in PTA patients than AT patients, but did not observe differences in CRP levels. In addition, higher serum CRP (S-CRP) levels predicted slower healing after PTA; the mean S-CRP in PTA patients was 85 mg/l (1.3--380 mg/l) \[[@pone.0228122.ref013], [@pone.0228122.ref014]\].

Salivary amylase levels can serve as a marker of salivary function, and recent studies have shown that both serum and pus amylase levels are highly elevated in PTA patients compared to patients with other neck abscesses and dental abscesses. In PTA patients, the mean serum amylase level is 50 U/l and mean pus amylase level 3045 U/l (range 20--11,000 U/l) \[[@pone.0228122.ref015]--[@pone.0228122.ref017]\].

Group A streptococci (GAS) are the most prevalent bacteria causing both AT and PTA \[[@pone.0228122.ref009]--[@pone.0228122.ref011], [@pone.0228122.ref018]\]. Several studies have reported other bacteria (e.g., other beta-hemolytic streptococci \[groups C and G\] and *Fusobacterium necrophorum* \[FN\]) as major pathogens in AT \[[@pone.0228122.ref019], [@pone.0228122.ref020]\], and FN has been recognized as a major pathogen in PTA. In addition, *Streptococcus anginosus* group (SAG) streptococci have been reported as important pathogens in peritonsillar infections and observed to predict the recurrence of PTA \[[@pone.0228122.ref021], [@pone.0228122.ref022]\]. PTAs caused by FN are associated with significantly increased CRP and neutrophil levels compared to PTAs caused by other pathogens \[[@pone.0228122.ref022]\].

Although the clinical picture of PTAs is diverse, previous studies concerning PTA diagnostics have considered these patients as a uniform group. The aim of this study was to clarify the potential role of minor salivary glands in the development of PTA and to specify diagnostics for PTA.

Materials and methods {#sec002}
=====================

Participants and samples {#sec003}
------------------------

The study included 112 patients referred to Helsinki University Hospital Department of Otorhinolaryngology for AT or PTA between February and October 2017. Exclusion criteria were age \<15 years or pancreatic disease due to the changes in serum amylase levels caused by pancreatic destruction \[[@pone.0228122.ref023]\]. Patients were divided into two subgroups based on clinical diagnosis: AT (n = 54) or PTA (n = 58). All patients completed a questionnaire concerning their smoking habits, overall health, current disease, prior antibiotics during the current infection, alcohol consumption, and previous tonsillar or peritonsillar infections. The emergency department physician completed a structured form concerning tonsillar findings, and the physicians evaluated the dental health and oral hygiene (good/poor) by inspecting the oral cavity. Blood samples were collected from all patients, and S-CRP and serum amylase (S-Amyl) levels were analyzed. The PTA patients were also treated with incision and drainage (ID). Pus aspirate samples from PTA patients and throat swabs from AT patients were taken for bacterial culture.

Bacterial culture was performed at Helsinki University Hospital Laboratory Services (HUSLAB). Pus samples were grown under both aerobic and anaerobic conditions and the superficial throat swabs under aerobic conditions according to the laboratory's standard methods for diagnostic samples. The bacterial culture results were recorded from the hospital laboratory database as reported by the diagnostic laboratory. For the analysis, all isolates of beta-hemolytic streptococci, SAG and FN, *Haemophilus influenzae*, *Staphylococcus aureus*, and heavy growth of *Neisseria meningitidis* were recorded as separate isolates. Non-FN anaerobic isolates were combined and classified as other anaerobic bacteria. In addition, the reported mixed normal flora was recorded as mixed regional flora.

Ethical considerations {#sec004}
----------------------

All procedures that involved human participants were conducted in accordance with the ethical standards of the institutional or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The Ethics Committee of Helsinki University Hospital approved the study protocol. All patients provided written informed consent prior to their participation. According to Finnish legislation, minors over 15 years of age are entitled to give their informed consent without guardian's permission. All provided study information was, however, adjusted for their age group.

Main outcome measures {#sec005}
---------------------

Correlations between smoking, alcohol consumption, signs and symptoms of infection, laboratory tests, oral health, and bacterial findings were analyzed and compared between the AT and PTA patients. The main aim of these analyses was to determine whether any differences were present in laboratory tests, oral health, or symptoms between AT and PTA patients. In addition, we examined whether different subgroups of AT or PTA patients exist and whether laboratory values, bacterial findings, certain symptoms, smoking, or oral health are related to a specific subgroup of patients.

Statistical analysis {#sec006}
--------------------

Statistical analyses were performed using NCSS 8 statistical software (Hintze, J. \[2012\]; NCSS 8, NCSS, LLC, Kaysville, UT, USA; [www.ncss.com](http://www.ncss.com/)). The FN and FN+SAG groups were combined in the statistical analysis due to the small number of patients in the groups. Numerical variables were analyzed by the Mann-Whitney U-test and Kruskal-Wallis one-way ANOVA. Chi-squared was applied to compare nominal variables. The Spearman rank-correlation was applied to two numerical variables with non-normal distribution. *P-*values \<0.05 were considered significant.

Results {#sec007}
=======

A total of 112 patients were included in the study. Patient characteristics and clinical data are presented in [Table 1](#pone.0228122.t001){ref-type="table"}. None of the patients developed a complication during the first 3 months.

10.1371/journal.pone.0228122.t001

###### Patient characteristics.

![](pone.0228122.t001){#pone.0228122.t001g}

  Characteristic                                                             All PTA patients (n = 58)   AT patients (n = 54)   PTA patients without tonsillar findings (n = 8)
  -------------------------------------------------------------------------- --------------------------- ---------------------- -------------------------------------------------
  Age, years                                                                                                                    
  Median                                                                     36                          28.5                   50.5
  Range                                                                      16--65                      15--86                 24--65
  Gender                                                                                                                        
  Male                                                                       36 (62.1)                   21 (38.9)              5 (62.5)
  Female                                                                     22 (37.9)                   33 (61.1)              3 (37.5)
  Smoking                                                                                                                       
  Non-smoker                                                                 21 (36.8)                   20 (37.0)              5 (62.5)
  Smoker                                                                     24 (41.4)                   22 (40.7)              2 (25.0)
  Ex-smoker                                                                  12 (20.7)                   12 (22.2)              1 (12.5)
  No information                                                             1                                                  
  Alcohol consumption                                                                                                           
  Yes                                                                                                                           
  No                                                                         36 (62.1)                   31 (57.4)              4 (50.0)
  No information                                                             21 (36.2)                   23 (42.6)              4 (50.0)
                                                                             1                                                  
  Prior antibiotics for more than 24 hours                                                                                      
  Yes                                                                        10 (17.2)                   9 (16.7)               1 (12.5)
  No                                                                         48 (82.8)                   45 (83.3)              7 (87.5)
  Duration of symptoms [^a^](#t001fn002){ref-type="table-fn"} prior to PTA                                                      
  1--3 Days                                                                                                                     
  \>3 days                                                                                                                      
                                                                             16 (27.6)                   28 (51.9)              2 (25.0)
                                                                             42 (72.4)                   26 (48.1)              6 (75.0)
  Unilateral throat pain                                                                                                        
  Yes                                                                        54 (93.1)                   31 (60.8)              8 (100.0)
  No                                                                         4 (6.9)                     20 (39.2)              0 (0)
  No information                                                                                         3                      
  Fever                                                                                                                         
  Yes                                                                        38 (65.5)                   41 (75.9)              3 (37.5)
  No                                                                         20 (34.5)                   13 (24.1)              5 (62.5)
  Symptoms of common cold                                                                                                       
  Yes                                                                                                                           
  No                                                                         16 (27.6)                   23 (44.2)              2 (25.0)
  No information                                                             42 (72.4)                   29 (55.8) 2            6 (75.0)
  Prior tonsillar infection                                                                                                     
  AT                                                                         13 (22.8)                   12 (22.2)              0(0)
  CT                                                                         1 (1.8)                     1 (1.9)                0 (0)
  PTA                                                                        8 (14.0)                    2 (5.6)                2 (25.0)
  None                                                                       35 (61.4)                   38 (70.4)              6 (75.0)
  No information                                                             1                                                  
  Tonsillar findings                                                                                                            
  Exudate                                                                                                                       
  Erythema                                                                   16 (28.1)                   16 (30.2)              0 (0)
  Both                                                                       26 (45.6)                   16 (30.2)              0 (0)
  None                                                                       7 (12.3)                    21 (39.6)              0 (0)
  No information                                                             8 (14.0)                    0 (0)                  8 (100.0)
                                                                             1                                                  
  Oral hygiene                                                                                                                  
  Good                                                                                                                          
  Poor                                                                       52 (91.2)                   48 (90.6)              7 (87.5)
  No information                                                             5 (8.8)                     5 (9.4)                1 (12.5)
                                                                             1                           1                      

Data are presented as n (%) unless otherwise noted. PTA, peritonsillar abscess; AT, acute tonsillitis; CT, chronic tonsillitis

^a^ Throat pain, fever, hoarseness.

Serum amylase and C-reactive protein levels {#sec008}
-------------------------------------------

A significant inverse correlation was observed between S-Amyl (normal reference 28--100 U/l) and S-CRP (normal reference 0.05--3 mg/l) levels in both the AT and PTA groups (AT, r = -0.519, *p*≤0.001; PTA, r = -0.353, *p*≤0.001; [Fig 1](#pone.0228122.g001){ref-type="fig"}). We found no differences in the S-Amyl or S-CRP levels between the AT and PTA groups (S-Amyl, *p* = 0.767; S-CRP, *p* = 0.501). Alcohol consumption and smoking habits had no effect on S-Amyl levels (alcohol, *p* = 0.750; smoking, *p* = 0.205). No correlation was found between age and CRP (AT and PTA patients r = -0.094, *p* = 0.342; PTA patients r = -0.137, *p* = 0.329). The S-Amyl and S-CRP levels in AT and PTA patients are presented in [Table 2](#pone.0228122.t002){ref-type="table"}.

![Correlation between serum amylase and C-reactive protein levels.\
(A) Patients with acute tonsillitis (r = -0.519, *p*≤0.001). (B) Patients with peritonsillar abscess (r = -0.353, p ≤0.001).](pone.0228122.g001){#pone.0228122.g001}

10.1371/journal.pone.0228122.t002

###### Serum amylase and CRP levels in AT (n = 52) and PTA (n = 54) patients with different infection symptoms.

![](pone.0228122.t002){#pone.0228122.t002g}

                     Median amylase in AT (U/l)   Median CRP in AT (mg/l)   Median amylase in PTA (U/l)   Median CRP in PTA (mg/l)
  ------------------ ---------------------------- ------------------------- ----------------------------- --------------------------
  Fever                                                                                                   
      Yes            37.5                         104.5                     44                            82
      No             65.5                         15                        46                            40
      p-value        0.0212                       0.00037                   0.637                         0.239
  Symptom duration                                                                                        
      \<3 days       39                           94                        36                            74
      \>3 days       42                           80                        44                            59
      p-value        0.650                        0.063                     0.655                         0.720
  Unilateral pain    46                           75.5                      44                            60
  Bilateral pain     30.5                         110                       32.5                          120.5
      p-value        0.033                        0.031                     0.175                         0.522
  Common cold                                                                                             
      Yes            41                           94                        51                            36
      No             38.5                         90                        41                            82
      p-value        0.914                        0.575                     0.0096                        0.0755
  Oral hygiene                                                                                            
      Normal/Good    39.5                         87                        41                            67
      Poor           42                           92                        48                            36
      p-value        0.862                        0.874                     0.484                         0.447
  History of                                                                                              
      AT             34                           90                        46                            105
      PTA                                                                   35                            36
      None           44                           83                        44                            56
      p-value        0.151                        0.971                     0.852                         0.409

AT, acute tonsillitis; PTA, peritonsillar abscess

Tonsillar findings {#sec009}
------------------

In patients with AT, the presence of tonsillar erythema, tonsillar exudate, or both had no effect on S-Amyl (*p* = 0.306) or S-CRP (*p* = 0.363) levels. In the PTA group, eight patients did not have tonsillar erythema or tonsillar exudate. These eight PTA patients had significantly lower S-CRP levels (median 15 mg/l, range 3--40 mg/l) than PTA patients presenting with tonsillar findings (median S-CRP 60 mg/l, range 3--313 mg/l; *p*\<0.001). S-Amyl levels were slightly, but not significantly (*p* = 0.190), higher in these eight patients (median 49 U/l, range 27--82 U/l) compared to the other PTA patients (median 41 U/l, range 15--116 U/l; [Fig 2](#pone.0228122.g002){ref-type="fig"}). PTA patients without tonsillar findings were significantly older (median age 50.5 years, range 24--65 years) than the other PTA patients (median age 34 years, range 16--60 years; *p* = 0.006). Of the 58 PTAs, two (3.4%) were bilateral. Oral health had no impact on bacterial findings in either group.

![Distribution of serum proteins in PTA patients with different tonsillar findings.\
(A) C-reactive protein (S-CRP) and (B) amylase (S-Amyl). 1, tonsillar erythema; 2, tonsillar exudate; 3, no findings; 4, tonsillar erythema and exudate.](pone.0228122.g002){#pone.0228122.g002}

Bacterial findings {#sec010}
------------------

Bacterial samples were taken from all but two PTA patients. The bacterial findings are presented in [Table 3](#pone.0228122.t003){ref-type="table"}. The most common bacteria isolated in AT patients were GAS (41.7% of all samples), group B, C, and G beta-hemolytic streptococci (3.7%), and *H*. *influenzae* (3.7%). In 51.9% of AT patients, only normal mixed tonsillar flora was reported. In PTA patients, anaerobic Gram-negative rods were a common finding (n = 27, 37.5% of all samples), including FN isolated from five patients. GAS and SAG were isolated from an almost equal number of samples (18.1% vs. 15.3%). In three samples, SAG was found together with FN. *H*. *influenzae*, *N*. *meningitidis*, and *S*. *aureus* isolates were found together with anaerobic Gram-negative rods. *N*. *meningitidis* growth was heavy and included as a separate finding. One bacterial sample in the PTA group was negative.

10.1371/journal.pone.0228122.t003

###### Bacterial findings in patients with AT or PTA.

![](pone.0228122.t003){#pone.0228122.t003g}

  Variable                                                                                         AT[^a^](#t003fn002){ref-type="table-fn"}   PTA
  ---------------------------------------------------------------- ------------------------------- ------------------------------------------ -----------
  **Number of samples**                                                                            54                                         56
  **Bacterial findings, n (%)**                                                                                                               
  **Aerobic bacteria**                                                                                                                        
  Beta-hemolytic streptococci                                                                      24 (44.4)                                  16 (22.2)
                                                                   Group A streptococci            22 (40.7)                                  13 (18.1)
                                                                   Group B, C, or G streptococci   2 (3.7)                                    3 (4.2)
  *Streptococcus anginosus* group                                                                  0 (0)                                      11 (15.3)
  *Haemophilus influenzae*                                                                         2 (3.7)                                    1 (1.4)
  *Neisseria meningitidis*                                                                         0 (0)                                      1 (1.4)
  *Staphylococcus aureus*                                                                          0 (0)                                      3 (4.2)
  Other aerobic bacteria                                                                           0 (0)                                      0 (0)
  **Anaerobic bacteria**                                                                                                                      
  *Fusobacterium necrophorum*                                                                                                                 5 (6.9)
  Other anaerobic bacteria[^b^](#t003fn003){ref-type="table-fn"}                                                                              22 (30.6)
  **Mixed regional flora**                                                                         28 (51.9)                                  13 (18.1)

AT, acute tonsillitis; PTA, peritonsillar abscess

^a^ Only aerobic culture was performed for patients with acute tonsillitis (AT).

^b^ Other anaerobic bacteria isolated: anaerobic Gram-negative rods (n = 14), *Prevotella* species (n = 2), *Fusobacterium* species other than necrophorum (n = 4), anaerobic mixed flora (n = 2).

The bacteria isolated from the eight PTA patients without tonsillar findings were GAS (n = 2), *S*. *aureus* (n = 2), FN (n = 1), anaerobic Gram-negative rods (n = 5), and mixed aerobic flora (n = 1). *S*. *aureus* was isolated together with anaerobic Gram-negative rods in both cases. All of these bacteria were also isolated in other PTA patients; therefore, we found no obvious difference between the two groups in the bacterial etiology of the disease.

No differences were found in the S-Amyl or S-CRP levels between the bacterial findings in either the AT or PTA group (AT, S-Amyl *p* = 0.620, S-CRP *p* = 0.331; PTA, S-Amyl *p* = 0.925, S-CRP *p* = 0.203). Bacterial findings were not associated with any of the recorded specific symptoms (unilaterality, absence of common cold, fever) or presence of tonsillar erythema or exudate in the AT or PTA group. Oral health had no impact on bacterial findings in either group.

In patients treated with prior antibiotics, SAG was found more frequently than other bacteria (*p* = 0.037). Patients with SAG were significantly older (median age 45 years, range 27--53 years) than patients with the following other bacteria: GAS (median age 30 years, range 20--58 years), non-SAG/beta-hemolytic streptococci/FN (median age 31.5 years, range 18--65 years), or FN and FN+SAG (median age 25.5 years, range 16--37 years; *p* = 0.022). Seven out of nine patients (77.8%) with SAG were male.

Discussion {#sec011}
==========

Some of the PTA patients in this study had no tonsillar findings at clinical examination. In contrast, all AT patients had tonsillar erythema, tonsillar exudate, or both. PTA patients presenting without tonsillar erythema and tonsillar exudate had significantly lower S-CRP levels than PTA patients with tonsillar findings. These eight patients without tonsillar findings were also older than other PTA patients. Thus, patient characteristics, S-CRP, S-Amyl, and clinical findings may be tools for differentiating PTA patient subgroups with different etiological factors \[[@pone.0228122.ref003], [@pone.0228122.ref005]\]. In addition, we found an inverse correlation between S-Amyl and S-CRP levels and lower S-CRP and higher S-Amyl levels in afebrile AT patients compared to those with fever.

Strengths and limitations of the study {#sec012}
--------------------------------------

This prospective study is the first study to compare both S-CRP and S-Amyl between AT and PTA patients, as well as between patients with different signs and symptoms of infection. One limitation of this study is that only aerobic bacteria were analyzed in superficial throat bacterial cultures. In addition, though both aerobes and anaerobes were tested in pus samples, some bacterial findings were so few that it limited the statistical analysis. We did not exclude AT patients with earlier PTA (n = 3) from the study, which could have affected the results, but our cohort included very few of these patients. Patients with alcohol abuse and pancreatic disease were excluded from the study, and none of the patients were pregnant, but patients with other conditions causing elevated S-Amyl, such as gastrointestinal tract infections, eating disorders, drug use, renal dysfunction, and macroamylasemia, were not excluded. Furthermore, the evaluation of tonsillar findings (erythema, exudate) was based on subjective observation by ear, nose, and throat physicians. However, due to prospective nature of the study, as well physicians' substantial experience with tonsillar diseases, the evaluation can be considered reliable. Oral health was also evaluated by an ear, nose, and throat physician, not a dentist, and classified only as good/poor. We used the standard reference values to analyze S-Amyl and did not have the baseline S-Amyl value for the 112 patients. Therefore, it is impossible to determine the actual change in S-Amyl values caused by the infection. Our material is consistent with previous studies concerning patient age, gender, oral health, and smoking habits \[[@pone.0228122.ref002], [@pone.0228122.ref009], [@pone.0228122.ref019], [@pone.0228122.ref024]\].

Comparison with other studies {#sec013}
-----------------------------

No earlier studies have compared S-CRP and S-Amyl levels between PTA patients with different signs and symptoms. In our study, we observed a group of PTA patients without tonsillar findings. Compared to patients with AT or PTA with tonsillar findings, these patients had lower S-CRP levels and were older. In AT and PTA patients, an inverse correlation between S-Amyl and S-CRP levels was evident. Similar findings have been reported in patients with infection of major salivary glands. Saarinen et al. demonstrated that the majority of patients suffering from parotitis had elevated S-Amyl levels (median 261 U/l, range 24--1220), but only half of the patients had significantly elevated S-CRP levels \>40 mg/l; 32% of the patients had normal S-CRP \< 5 mg/l (median 13.0 mg/l, range 5--170 mg/l) \[[@pone.0228122.ref025]\]. These similar findings between our eight PTA patients and patients with confirmed infection of the major salivary glands suggests that the PTA in these eight patients was due to infection of the minor salivary glands \[[@pone.0228122.ref025]--[@pone.0228122.ref028]\]. One possible reason that S-Amyl levels in PTA patients remain below the reference values is the small size of the minor salivary glands relative to major salivary glands, which prevents the elevation from becoming substantial. In addition, S-Amyl reference values are validated for the diagnosis of pancreatic diseases and may not be directly adaptable to reflect the activity of minor salivary glands. For a more reliable analysis of changes in S-Amyl in PTA patients, we should define the baseline S-Amyl levels in these patients and prefer S-Amyl measurements over salivary amylase.

We found no difference in S-Amyl levels between patients with and without a history of recurrent AT or PTA. This observation differs from an earlier study demonstrating significantly lower pus amylase levels in patients with a recurrent PTA \[[@pone.0228122.ref016]\]. Tachibana et al. previously showed no difference in S-CRP levels between AT and PTA patients. Our observations were similar \[[@pone.0228122.ref014]\].

We also observed that afebrile AT patients have lower S-CRP and higher S-Amyl levels than AT patients with fever. One could speculate that salivary gland activation sometimes occurs in AT, though this hypothesis has not been presented previously \[[@pone.0228122.ref004], [@pone.0228122.ref029]\]. AT patients with unilateral symptoms had lower S-CRP and higher S-Amyl levels than patients with bilateral throat pain, which could also indicate activity in the minor salivary glands. We compared S-Amyl levels between PTA and AT patients and did not observe a difference between the groups. El Saied et al. previously demonstrated a difference in both serum and pus amylase levels between PTA patients and patients with deep neck abscesses and dental abscesses \[[@pone.0228122.ref016], [@pone.0228122.ref017]\].

In our study, GAS was the most prevalent bacterial finding in PTA patients, followed by SAG and FN. In a recent Danish study of PTA, FN was the predominant pathogen, GAS was the second most common, and group C *Streptococcus* was the third \[[@pone.0228122.ref022]\]. In this study, SAG was found in older patients and predominately in males. Furthermore, SAG has been shown to predict the rapid recurrence of PTA and to be found in older male patients \[[@pone.0228122.ref021], [@pone.0228122.ref030]\].

Clinical applicability of the study {#sec014}
-----------------------------------

Our results suggest that the pathogenesis of PTA may differ between patients; thus, patient characteristics, S-CRP and amylase levels, and clinical findings may be useful tools for differentiating these PTA subgroups. For example, when differentiating between subgroups of PTA patients, we could identify patients who would benefit from TE after the first PTA episode. Further studies are needed to clarify the usability of these variables and their significance in helping choose the optimal treatment strategy for different PTA patients.

Conclusion {#sec015}
==========

The etiology of PTA is not as unambiguous as previously thought. Bacteria may not be the only factor determining the course of the disease. There seems to be a subgroup of PTA patients without signs of tonsillar infection that share features with parotitis. Therefore, it may be possible for PTA in these patients to not begin as a complication of AT, but as an infection of the minor salivary glands. More research is needed to examine the different subgroups of PTA and the role of minor salivary glands in PTA and AT.
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PTA

:   Peritonsillar abscess

AT

:   acute tonsillitis

GAS

:   Group A streptococcus

FN

:   *Fusobacterium necrophorum*

SAG

:   *Streptococcus anginosus* group

ID

:   incision and drainage
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Reviewer 2: Abstract line 11: suggest changing to: \"These findings support that some cases of PTA may be caused by an etiology other than AT. \"

Response: Abstract lines 11-12 changed.

Reviewer 2: Would add to keywords; peritonsillar abscess, tonsillitis

Response: peritonsillar abscess, tonsillitis added to keywords

Reviewer 1: Weber´s glands should be quoted

Response: Weber´s glands are added to introduction, page 4, line 9.

Reviewer 2: Page 11 line 25: Suggest not using the abbreviation TE (eg write out the words)

Response: Page 11 line 4 as suggested

Reviewer 2: It is a stretch to say that there is a group of patients who share features with parotitis. Suggest limiting the conclusion to what is known- i.e. the inverse relationship between CRP and S-amyl.

Response: Page 11, line 15 changed as suggested.

Reviewer 1: Although a well written paper with a coherent statistical analysis of the data, it is not a new suggestion in the literature regarding the relationship of PTA and the minor salivary glands of Weber (this eponym should have been quoted \...). Other than that, for validation of microbial etiology swabs of the tonsillar surface in the PTA patients should also have been done as for individual comparison of microbial etiology and for comparison with the AT patients. As regarding the s-Amyl levels, the findings could possibly have other causes; in this way, the s-Amyl levels should also have been measured after disease resolution as to exclude false-positive results during PTA crisis.

Response: Thank you for your comments. We are not suggesting that the relationship of PTA and minor salivary glands is our original idea. See the introduction Page 4, Lines 6-9: "Over the last three decades, PTA has been speculated to not necessarily arise from AT, but as a consequence of poor dental health, smoking, and salivary dysfunction. Minor salivary glands have been suggested to play a significant role in PTA. "

The idea about validation microbial etiology by comparing the superficial throat swabs between AT and PTA patients is good, and we are definitely considering that in our next study. B
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Other causes that could elevate the S-Amyl levels are listed in discussion: page 9, lines 23-26. The follow up of S-Amyl levels after recovery would increase the reliability of our findings, but because of the nature of prospective study we have no possibility to get this information afterwards. However, by excluding the known causes of elevated S-Amyl levels we can quite reliably assume that the elevated S-Amyl levels are caused by PTA .
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